Drug & intervention

daraxonrasib

RxCUI 2750155

Clinical trials6
Recruiting5
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

6 shown
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)NCT07492680 · 2026-07-27
RECRUITING
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsNCT07397338 · 2026-01-30
RECRUITING
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsNCT07349537 · 2026-01-08
RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784 · 2025-05-06
RECRUITING
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsNCT06128551 · 2023-11-14
RECRUITING
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerNCT07793253 · 2026-11-01
NOT_YET_RECRUITING

Conditions being studied

Non-small Cell Lung Cancer (NSCLC)3NSCLC3Advanced Solid Tumors2Colorectal Cancer (CRC)2CRC2Ampulla of Vater Carcinoma1Ampullary Carcinoma1Biliary Tract Cancers1Colorectal Cancer1Extrahepatic Cholangiocarcinoma1Gallbladder Carcinoma1Intrahepatic Cholangiocarcinoma (Icc)1Lung Cancer (NSCLC)1Metastatic Solid Tumors1Non-Small Cell Lung Cancer1NSCLC (Advanced Non-small Cell Lung Cancer)1NSCLC (Non-small Cell Lung Cancer)1NSCLC (Non-small Cell Lung Carcinoma)1Pancreatic Adenocarcinoma1Pancreatic Cancer1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.